Trial Profile
A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Amcasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America; Sumitomo Pharma Oncology
- 22 Jan 2021 Status changed from active, no longer recruiting to completed.
- 26 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2020.
- 30 Mar 2018 Status changed from recruiting to active, no longer recruiting.